Publicaciones en las que participa el autor/a Naranjo ME

13

Development of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes.

Autores

De Andrés F, Dorado P, Llerena A, Machín E, Naranjo ME, Peñas-Lledó EM

16

Eating Disorder Symptoms and CYP2D6 Variation in Cuban Healthy Females: A Report from the Ibero-American Network of Pharmacogenetics.

Autores

Alvarez M, Calzadilla LR, Dorado P, González I, Llerena A, Naranjo ME, Peñas-Lledó EM, Pérez B

17

CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.

Autores

Alonso E, Dorado P, Jung H, Llerena A, López M, Naranjo ME, Ortega-Vázquez A, Peñas-Lledó EM, Trejo HD

22

Evaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail.

Autores

De Andrés F, Lazalde-Ramos BP, Llerena A, Naranjo ME, Sosa-Macías M, Tarazona-Santos E

23

Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications.

Autores

Albuquerque J, Grazina M, Llerena A, Naranjo ME, Ribeiro C

25

CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.

Autores

Alvarez M, Calzadilla LR, Dorado P, González I, Llerena A, Naranjo ME, Peñas-Lledó EM, Pérez B, Ramírez R

30

CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico.

Autores

Galaviz-Hernández C, Garza-Veloz I, Lazalde-Ramos BP, Llerena A, Martínez-Fierro ML, Naranjo ME, Sosa-Macías M

35

Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.

Autores

Fariñas H, Llerena A, Naranjo ME, Peñas-Lledó EM, Rodrigues-Soares F, Tarazona-Santos E

36

Ethnic background and CYP2D6 genetic polymorphisms in Costa Ricans.

Autores

Barrantes R, Céspedes-Garro C, Jiménez-Arce G, Llerena A, Naranjo ME

38

CYP2D6 ethnic variability in Hispanics.

Autores

Dorado P, Llerena A, Naranjo ME, Peñas-Lledó EM

43

Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes.

Autores

Céspedes-Garro C, De Andrés F, Fariñas H, Fricke-Galindo I, Llerena A, López M, Naranjo ME, Peñas-Lledó EM, Rodrigues-Soares F

44

Pharmacogenetics in Central American healthy volunteers: interethnic variability.

Autores

Barrantes R, Céspedes-Garro C, Fariñas H, Llerena A, Naranjo ME, Ramírez R, Serrano V

45

High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.

Autores

Apellániz-Ruiz M, Carracedo A, Cascón A, Comino-Méndez I, Currás-Freixes M, De Cubas AA, Grazina M, Ingelman-Sundberg M, Inglada-Pérez L, Llerena A, Mancikova V, Moya GE, Naranjo ME, Opocher G, Rasool M, Rebai A, Robledo M, Rodríguez-Antona C., Sánchez L, Taboada-Echalar P, Triki S

50

Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations.

Autores

Céspedes-Garro C, De Andrés F, Delgado A, Fricke-Galindo I, Llerena A, López M, Naranjo ME, Peñas-Lledó EM, Rodrigues-Soares F

53

Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19 and CYP2D6 polymorphisms in a multiethnic Costa Rican population.

Autores

Barrantes R, Céspedes-Garro C, Fariñas H, Jiménez-Arce G, Llerena A, Naranjo ME, Rodrigues-Soares F, Tarazona-Santos E

54

High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Autores

Cobaleda J, De Andrés F, Delgado A, Llerena A, Naranjo ME, Peñas-Lledó EM

56

Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Autores

Campos ML, Céspedes-Garro C, Duconge J, Fariñas H, Llerena A, Montané-Jaime LK, Naranjo ME, Peñas-Lledó EM, Ramírez R, Roblejo H, Rodrigues-Soares F, Serrano V, Villagrán CI

64

Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.

Autores

Calzadilla LR, De Andrés F, Dorado P, González I, Llerena A, Naranjo ME, Peñas-Lledó EM

65

High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.

Autores

Dorado P, Ferreiro V, Llerena A, Moya GE, Naranjo ME, Peñas-Lledó EM

66

CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?

Autores

De Andrés F, Llerena A, Naranjo ME, Ramos BPL, Sosa-Macías M

68

Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.

Autores

Barrantes R, Calzadilla LR, Estévez-Carrizo FE, Fariñas H, Grazina M, Llerena A, López M, Moya GE, Naranjo ME, Ortiz-López R, Peñas-Lledó EM, Ramírez R, Rodeiro I, Rodrigues-Soares F, Sarmiento AP, Sosa-Macías M, Tarazona-Santos E, Terán E